On Thursday, Dentsply Sirona mentioned it has suspended gross sales and advertising and marketing of its enamel aligners — Byte Aligners and Impression Kits — following a voluntary determination made in session with the U.S. Meals and Drug Administration (FDA) to make sure compliance with U.S. laws.

“The corporate holds itself to the very best requirements of high quality, with affected person security on the centre of all the things we do,” it mentioned in a press launch.

Dentsply Sirona mentioned it is going to proceed to work with the FDA and different regulatory authorities whereas speaking with treating dentists and their sufferers.

Moreover, adjustments in state laws throughout the U.S. have made it tougher for the corporate to promote these merchandise. The corporate didn’t present particular particulars concerning the new necessities.

Dentsply Sirona has begun reallocating sources from Byte to different areas of its enterprise. “We had begun to evaluate our sources at Byte to leverage and/or redeploy infrastructure, expertise, and functionality elsewhere in our enterprise,” it mentioned. “Examples embody augmenting sources to enhance different software program platforms, accelerating DS Core performance, and enhancing the affected person expertise.”

The corporate emphasised that the suspension solely applies to the Byte enterprise. Its different aligner enterprise, equivalent to SureSmile, stays unaffected.

The corporate additionally offered preliminary third-quarter outcomes, anticipating to report web gross sales of about $951 million and an adjusted revenue of between 49 and 51 cents per share. In keeping with information compiled by LSEG, analysts had forecasted gross sales of $937.91 million and adjusted revenue of 47 cents per share.